Background. In head failure, hyperphosphorylation of ryanodine receptor (RyR) mediated through PKA has been shown to cause dissociation of FKBP12.6 from RyR, resulting in an abnormal Ca 2+ leak through RyR and possibly consequent cardiac dysfunction. Here, we assessed whether ~-blookede can restore this defective channel function of RyR and therefore improve cardiac function in heart failure. Methods and Results, Sarcoplasmic retioulum (SR) was isolated from dog LV muscles {normal (N), n=5; 4-weeks RV pacing with or without propranolol [P(+): n=4, P(-): n=5, respectively]}. In normal dogs, the dose of propranolol (0.05 mg/kg/day, iv) decreased head rate at baseline by 14 %, but did not attenuate the isoproterenol (0.8 pg/kg/min)-induced increase in peak +dP/ dt of LV pressure. 1) As compared with pre-RV pacing, both end-diastolic [36.2mm in P(+) versus 41.9mm in P(-), p<0.05] and end-systolic diameter [29.4mm in P(+) versus 37.5mm in P(-), p<0.05] were less increased in P(+) than P(-), associated with lesser decrease in fractional shortening [19.0% in P(+) versus 10.2% in P(-), p<0.05]. 2) In SR from P(-), a prominent Ca 2+ leak was observed and FK506 that dissociates FKBP12.6 from RyR did not induce further Ca 2+ leak because of a partial loss of FKBP12.6 from RyR. However, there was no appreciable Ca 2+ leak in SR from P(+), and FK506-inducad Ca 2+ leak was elicited like normal SR. 3) RyR was labeled in a sita-directed fashion with the fluorescent conformational probe methylcoumadn acetate (MCA). In SR from P(+),
the FK506-inducad increase in MCA fluorescence, which was virtually absent in SR from P(-), was observed like in normal SR. 4) Indeed, both stoichiometry of FKBP12.6 versus RyR assessed by [3H]FKS06 and [3H]ryanodine-binding assays [3.6 : 1 in N, 1.1 : 1 in P(-), 2.4 : 1 in P(+); p<0.05] and protein expression of FKBP12.6 assessed by Western Blot analysis were restored towards those in normal SR. Conclusions. Low dose of propranolol attenuated LV remodeling presumably by ameliorating the defective interaction of FKBP12.6 with RyR, presumably resulting in an inhibition of intracallular Ca 2+ overload and hence a prevention of the development of heart failure.
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Chronic Therapy With Metoprolol CR/XL Prevents Apoptosis Inducing Factor and Downregulates the Pro-Apoptotic Protein Bak in Cardiomyocytes of Dogs With
Heart Failure Anastassia V, Todor, Victor G. Sharov, George Suzuki, Hideaki Modta, Sidney Goldstein, Hani N. Sabbah, Henry Ford Health System, Detroit, Michigan.
Background: Chronic therapy with beta-adrenergic receptor antagonists in heart failure (HF) has been shown to attenuate cardiomyocyte apeptosis. We previously showed that beta-blockers also downregulate the expression of active caspase-3, a key enzyme that promotes nuclear DNA fragmentation, a hallmark of programmed cell death. Activation of caspase-3 is regulated, in part, by apeptosis inducing factor (AIF), a mitochonddal protein, which is activated by pro-apoptotic members of the Bcl-2 family that include Bak. In the present study, we examined the effects of chronic therapy with metoprotol CR/XL (ToproI-XL) on the expression of AtF and Bak in cardiomyocytes of dogs with chronic HF. Methods: HF was produced in 14 dogs by intracoronary microemboiizations. Dogs were randomized to 3 months of monotherapy with Toprol-XL (100 mg once daily, n=7) or to no therapy at all (control, n=7) . At the end of 3 months of therapy, dogs were sacrificed, and cardiomyocytes were enzymatically isolated from the LV free wall. Cardiomyocytes were also isolated from the LV free wall of 5 normal (NL) dogs and were used for comparisons. Expression of AIF was examined with Western blots using cytosolic fraction prepared from cardiomyocyte homogenate. Expression of Bak was also examined with Western blots using cardiomyocyte homogenate. Bands were quantified in densitometric units. Results: Expression of Bak was significantly increased in cardiomyocytes isolated from untreated HF dogs compared to NL (6.3 + 0.6 vs. 0.5 + 0.1, P<0.05). Treatment with ToproI-XL significantly decreased the expression of Bak (1.7 + 0.24) compared to untreated controls (P<0.05). Expression of AIF was significantly increased in cardiomyocytes isolated from untreated HF dogs compared to NL (6.3 _+ 0.4 vs. 4.3 + 0.2, P<0.05).
Treatment with ToproI-XL significantly decreased the expression of AIF (3.1 _+ 0.5) compared to untreated control (P<0.05). Conclusions: AIF and Bak are upregulatad in cardiomyocytes of dogs with HF. Chronic therapy with Toprol-XL attenuates the upregulation of both AIF and Bak. These data provide further support that long-term therapy with beta-blockers limits apoptosis-mediated ongoing cardiomyocyte loss in HF.
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Negative Modulation of Beta3-Adrenergic Stimulation on Cardiomyocyte Contractile Performance and [Ca2+]i Regulation Before and After Heart Failure: Insights Into the Underlying Cellular Mechanisms
Che-Pino Cheno. Katsuya Onishi, Heng-Jie Chang, Zhu-Shan Zhang, Tomohiko Ukai, Hiroshi Hasegawa, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Background:
We have previously reported that ~3-adrenergic receptor (AR) stimulation produces direct inhibition on LV contraction in conscious dogs before and after pacinginduced heart failure (CHF).
Methods:
To define the cellular mechanism, we assessed cell contraction, relaxation,
[Ca2+]i transient and Ca 2+ current (ICa,L) responses to BRL-37344 (BRL), a ~3-AR agonist in freshly isolated LV cardiomyocytes obtained from 7 instrumented dogs before and after pacing-induced CHF.
Results:
In normal myocytes, BRL (10"8M) caused significant decrease in cell contrac-
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tion measured as the percent shortening (SA, -29%, 9.1 vs 12.9%), the peak velocity shortening (dL/dtmax, -13%, 164.3 vs 189.3 ~m/sec) and reiengthening (dR/dtma x, -17%, 122.1 vs 146.3 I~m/sec) with parallel decreases in [Ca2+]l transient (-22%, 277.2 vs 331.3 nM) and ICa,L (-25%, 2.7 VS 3.6 pA/pF). In CHF myocytes, BRL produced much greater decreases in cell contraction and relaxation (SA, -46%, 4.1 vs 7.6%; dlJdtma x, -25%, 63.3 vs 64.7 Am/sec; dR/dtmax, -24%, 67.1 vs 88.4 Am/sec) with associated significantly greater reductions in peak [Ca2+] i transient (-32%, 181 .3 vs 270.1 nM) and ICa,L (-37%, 2.0 vs 3.2 pA/pF). These BRL-induced responses were not modified by pretreating myocytes with nadolol (10"5M), a ~1-and ~2-AR antagonist, but were prevented by bupranolol (10"aM), a ~3-antagonist. These responses were also nearly abolished by pretreating myocytes with PTX (2 ~g/ml, 6 hrs, 36°C) and dibutyryl-cAMP (5x10-4M). In contrast, BRL-induced decrease in SA (-12% vs -29%) was significantly attenuated by pretreatment with NOS inhibitor, L-NAME (10"4M, 30 min), but the BRL caused decreases in [Ca2+]i transient and ICa,L were not significantly altered.
Conclusion: 133-AR stimulation produces negative inotropic action in both normal and CHF myocytes due to decreased [Ca2+]i transient, ICe,L, and myocyte Ca 2+ sensitivity.
These effects are likely to be mediated through both NO-cAMP dependent and NOSindependent mechanisms that is coupled with PTX-sensitive G protein pathway and may involve a decreased level of cAMP.
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The Putative Beta Four-Adrenergic Receptor Is e Novel State of the Beta One-Adrenergic Receptor
